• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2022 Fiscal Year Final Research Report

Novel PET imaging of Abeta oligomer using cell- and BBB-penetrating microantibody

Research Project

  • PDF
Project/Area Number 19H03566
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 52010:General internal medicine-related
Research InstitutionOita University

Principal Investigator

Matsubara Etsuro  大分大学, 医学部, 教授 (70219468)

Co-Investigator(Kenkyū-buntansha) 佐々木 崇了  岡山大学, 医歯薬学域, 助教 (10461253)
藪内 健一  大分大学, 医学部, 助教 (10763807)
松浦 栄次  岡山大学, 中性子医療研究センター, 教授 (20181688)
Project Period (FY) 2019-04-01 – 2023-03-31
KeywordsAβオリゴマー / 画像バイオマーカー / PETイメージング
Outline of Final Research Achievements

In an AD mice model (APP-KI mice), brain positron emission tomography (PET) imaging by means of 89Zirconium (Zr)-labelled anti-Aβ oligomer-specific antibody, full-body type, revealed higher PET signal in the cortex compared with age-matched non-Ki mice. However, blood-brain barrier permeability was 0.05-0.1%, which is similar to the previous reports. To improve BBB-permeability, we used fragmented-antibody, which resulted in 10-20 times higher BBB permeability. However, no PET signal was detected in the cortex and hippocampus of APP-KI mice, indicating that diffusible soluble Aβ oligomer is difficult target to visualize in PET imaging.

Free Research Field

脳神経内科学

Academic Significance and Societal Importance of the Research Achievements

アルツハイマー病の疾患修飾薬であるレカネマブがFDAで迅速承認され、その適切使用を可能とする診断法、さらにより早期の診断治療法開発が世界中から切望されている。研究代表者らはより早期段階を標的とした先制医療薬開発を進め、その適応症例を選択する診断方法を本研究で進めてきた。この取り組みはアルツハイマー病の未来診断医療体制構築に不可欠で大きな学術的・社会的意義を有している。

URL: 

Published: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi